---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012085"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:24:38.128841+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mira-55 shows no cannabinoid-like CNS side effects in preclinical studies; advancing toward IND for inflammatory pain

## Summary
- Mira-55 tested at 10, 30, and 100 mg/kg in CNS assays; no psychogenic, motor, or anxiogenic effects observed.
- No catalepsy or sedation; dose-dependent increase in time spent in open arms of Elevated Plus Maze (anxiety reduction).
- Rimonabant (positive control) showed anxiety-like behavior, validating assay sensitivity.
- Prior data demonstrated Mira-55 produced morphine-comparable analgesia in inflammatory pain model without opioid risks.
- Company plans IND submission for inflammatory pain; additional preclinical studies ongoing.

## SEC filing metadata
- accession: 0001493152-26-012085
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226012085/0001493152-26-012085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226012085/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012085
- JSON: https://secwatch.observer/filing/0001493152-26-012085.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.